Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Heli Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6094-5776; OpenAlex author ID A5002990558. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 17

  1. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  2. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Co-author DOI 10.1002/jcla.24517↗
  3. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  4. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  5. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  6. Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. First author DOI 10.1016/j.bbcan.2020.188484↗
  7. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-021-02972-6↗
  8. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  9. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  10. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  11. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Co-author DOI 10.1186/s40164-020-00184-0↗
  12. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  13. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  14. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  15. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗
  16. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  17. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 16 shared papers, 2018–2024 · strength 1.84
  2. Wenquan Wang · 14 shared papers, 2018–2022 · strength 1.51
  3. Huaxiang Xu · 12 shared papers, 2018–2022 · strength 1.15
  4. Wuhu Zhang · 9 shared papers, 2019–2022 · strength 0.94
  5. Tianjiao Li · 8 shared papers, 2019–2022 · strength 0.83
  6. Chuntao Wu · 9 shared papers, 2018–2021 · strength 0.78
  7. Liang Liu · 7 shared papers, 2018–2022 · strength 0.72
  8. Shuo Li · 8 shared papers, 2018–2021 · strength 0.71
  9. Liang Liu · 6 shared papers, 2019–2022 · strength 0.61
  10. Xuan Han · 5 shared papers, 2020–2022 · strength 0.55
  11. Hao Li · 4 shared papers, 2019–2021 · strength 0.40
  12. Quanxing Ni · 5 shared papers, 2018–2019 · strength 0.38
  13. Xuan Lin · 3 shared papers, 2020–2022 · strength 0.33
  14. Long‐Yun Ye · 3 shared papers, 2020–2022 · strength 0.33
  15. Qifeng Zhuo · 2 shared papers, 2022–2024 · strength 0.33
  16. Wenyan Xu · 2 shared papers, 2022–2024 · strength 0.33
  17. Wensheng Liu · 2 shared papers, 2022–2024 · strength 0.33
  18. Xiaowu Xu · 2 shared papers, 2022–2024 · strength 0.33
  19. Shunrong Ji · 2 shared papers, 2022–2024 · strength 0.33
  20. Shirong Zhang · 4 shared papers, 2018–2019 · strength 0.31
  21. Jia Dong · 2 shared papers, 2021 · strength 0.27
  22. Xu Wang · 2 shared papers, 2021–2022 · strength 0.25
  23. Zhenyu Liao · 2 shared papers, 2021–2022 · strength 0.23
  24. Wang Jiang · 2 shared papers, 2020–2021 · strength 0.21
  25. Xinran Liu · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.